PharmaEngine, Inc. (TWO: 4162), announced today that the company has signed an Amendment to its License Agreement of MM-398 (aka PEP02, nanoliposomal irinotecan injection, nal-IRI) with Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK). This week Merrimack announced an exclusive license and collaboration agreement with Baxter International Inc. (NYSE: BAX) for MM-398 outside of the United States and Taiwan. PharmaEngine licensed the development, manufacturing and commercialization rights of PEP02 in Asia and Europe to Merrimack for US$220 million plus royalties and sublicense revenue in May 2011. In May 2014, the companies announced the successful completion of a global phase III study in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy.
Help employers find you! Check out all the jobs and post your resume.
